Monoclonal antibody · Inhibitor of MASP-2 · developed by Omeros
Narsoplimab-wuug is a monoclonal antibody that inhibits MASP-2, the effector enzyme of the lectin pathway of complement. By blocking lectin-dependent activation of complement components C3 and C4, it prevents complement-mediated cellular injury in small blood vessels.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03205995 | Phase 3 | Thrombotic Microangiopathies | Terminated | OMER |
| NCT03608033 | Phase 3 | IgA Nephropathy | Terminated | OMER |
| NCT05855083 | Phase 2 | Thrombotic Microangiopathies | Recruiting | OMER |
| NCT04247906 | N/A | Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy… | Approved for marketing | OMER |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hematopoietic Stem Cell TransplantationAtypical Hemolytic Uremic SyndromeIgA NephropathyThrombotic Microangiopathies
Updated Oct 3, 2026. Something wrong or missing? Report it on the OMER page.
See OMER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OMER catalysts and pipeline →